Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.

Human mutation - 1 Sept 2001

Bezieau S, Devilder M C, Avet-Loiseau H, Mellerin M P, Puthier D, Pennarun E, Rapp M J, Harousseau J L, Moisan J P, Bataille R

Abstract excerpt

Using allele-specific amplification method (ARMS), a highly sensitive one-stage allele-specific PCR, we have evaluated the incidence of NRAS and KRAS2 activating mutations (codons 12, 13, and 61) in 62 patients with either monoclonal gammopathy of undetermined significance (MGUS) or multiple myeloma (MM), primary plasma-cell leukemia (P-PCL), and also in human myeloma cell lines (HMCL). NRAS and/or KRAS2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Base Sequence
Share to DNA Mutational Analysis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Gene Frequency

Share to Genes, ras

Share to Multiple Myeloma

Share to Polymerase Chain Reaction

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 11524732
DOI: 10.1002/humu.1177

Genes

NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis.PMID 11524732Read ↗

Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias.Semantic proximity Read ↗

RAS mutations are uncommon in multiple myeloma and other monoclonal gammopathies.Semantic proximity Read ↗

Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III TrialSemantic proximity Read ↗

Loss of Heterozygosity and Mutations in the RAS-ERK Pathway Genes in Tumor Cells of Various Loci in Multiple Myeloma.Semantic proximity Read ↗

High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patientsSemantic proximity Read ↗

Relevance of Ras gene mutations in the context of the molecular heterogeneity of multiple myeloma.Semantic proximity Read ↗

Frequent functional activation of RAS signalling not explained by RAS/RAF mutations in relapsed/refractory multiple myeloma.Semantic proximity Read ↗

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy.Semantic proximity Read ↗

RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.Semantic proximity Read ↗

The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing.Semantic proximity Read ↗

Oncogenes in multiple myeloma: point mutation of N-ras.Semantic proximity Read ↗

p53 and RAS gene mutations in multiple myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.